Formulations of suberoylanilide hydroxamic acid and methods for producing same
View Patent ↗The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
1. A method of treating cancer in a patient comprising the step of orally administering to the patient a pharmaceutical composition comprising suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient in solid form, wherein about 100 mg of the active ingredient has an in vitro dissolution profile with a similarity factor (f2) of at least 56 to 100 compared to the reference dissolution profile of 52.7% dissolved at 10 minutes, 61.7% dissolved at 15 minutes, 67.7% dissolved at 20 minutes, 75.5% dissolved at 30 minutes, 82.6% dissolved at 45 minutes, and 87.0% dissolved at 60 minutes in vitro, wherein the dissolution profile is measured using a USP Dissolution Apparatus II with a helical sinker in 900 mL of 2.0% Tween at a temperature of 37±0.5° C., and paddles rotated at 100 rpm, and optionally a pharmaceutically acceptable excipient.
2. A method of treating cancer in a patient comprising the step of orally administering a pharmaceutical composition comprising suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient in solid form, wherein about 100 mg of the active ingredient has an in vitro dissolution profile of 46-60% dissolved at 10 minutes, 55-69% dissolved at 15 minutes, 61-75% dissolved at 20 minutes, 69-83% dissolved at 30 minutes, 76-90% dissolved at 45 minutes, and 80-94% dissolved at 60 minutes in vitro, wherein the dissolution profile is measured using a USP Dissolution Apparatus II with a helical sinker in 900 mL of 2.0% Tween at a temperature of 37±0.5° C., and paddles rotated at 100 rpm, and optionally a pharmaceutically acceptable excipient.
3. The method of claim 1 , wherein the % volume of active ingredient with particle sizes from about 120 to about 250 microns is in the range of about 4.0% to about 12%, and the % volume of active ingredient with particle sizes from about 35 to about 40 microns is in the range of about 3.0% to about 7%.
4. The method of claim 2 , wherein the % volume of active ingredient with particle sizes from about 120 to about 250 microns is in the range of about 4.0% to about 12%, and the % volume of active ingredient with particle sizes from about 35 to about 40 microns is in the range of about 3.0% to about 7%.
5. The method of claim 1 , wherein the pharmaceutical composition is formulated as a powder in a single capsule or tablet, wherein the amount of the active ingredient is about 100 mg of suberoylanilide hydroxamic acid; or is formulated as a powder in two capsules or tablets, wherein the amount of active ingredient in each capsule or tablet is about 50 mg of suberoylanilide hydroxamic acid.
6. The method of claim 1 , wherein the pharmaceutical composition is formulated as a powder in a single capsule or tablet, wherein the amount of the active ingredient is about 200 mg of suberoylanilide hydroxamic acid.
7. The method of claim 1 , wherein f2 is 60 to 100.
8. The method of claim 1 , wherein f2 is 65 to 100.
9. The method of claim 1 , wherein f2 is 70 to 100.
10. The method of claim 1 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
11. The method of claim 2 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
12. The method of claim 3 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
13. The method of claim 4 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
14. The method of claim 7 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
15. The method of claim 8 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
16. The method of claim 9 , wherein the pharmaceutical composition is formulated as a powder blend of the active ingredient with or without the excipient in capsule form.
17. The method of claim 10 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
18. The method of claim 11 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
19. The method of claim 12 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
20. The method of claim 13 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
21. The method of claim 14 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
22. The method of claim 15 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
23. The method of claim 16 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid.
24. The method of claim 10 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
25. The method of claim 11 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
26. The method of claim 12 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
27. The method of claim 13 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
28. The method of claim 14 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
29. The method of claim 15 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
30. The method of claim 16 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid and characterized by an X-ray diffraction pattern comprising characteristic peaks at 9.4, 17.5, 19.4, 20.0, 24.0 and 28.0 degrees 2θ using a Copper X-ray source.
31. The method of claim 1 , wherein the active ingredient is obtained by the process of:
(a) blending about 60-5% of a first batch of crystalline active ingredient having a mean particle size of less than about 60 μm and about 40-95% of a second batch of crystalline active ingredient having a mean particle size of about 100-250 μm; and
(b) encapsulating a portion of the blended crystalline active ingredient to produce the pharmaceutical composition.
32. The method of claim 1 , wherein the active ingredient is obtained by the process of:
(a) blending 40-20% of a first batch of crystalline active ingredient having a mean particle size of 25 to 45 μm and 60-80% of a second batch of crystalline active ingredient having a mean particle size of 130-180 μm; and
(b) encapsulating a portion of the blended crystalline active ingredient to produce the pharmaceutical composition.
33. The method of claim 32 , wherein step (a) comprises the step of:
blending 30% of a first batch of crystalline suberoylanilide hydroxamic acid having a mean particle size of 25 to 45 μm and 70% of a second batch of crystalline suberoylanilide hydroxamic acid having a mean particle size of 130-180 μm.
34. The method of claim 24 , wherein the active ingredient is obtained by the process of:
(a) blending 40-20% of a first batch of crystalline suberoylanilide hydroxamic acid having a mean particle size of 25 to 45 μm and 60-80% of a second batch of crystalline suberoylanilide hydroxamic acid having a mean particle size of 130-180 μm; and
(b) encapsulating a portion of the blended crystalline suberoylanilide hydroxamic acid to produce the pharmaceutical composition.
35. The method of claim 34 , wherein step (a) comprises the step of:
blending 30% of a first batch of crystalline suberoylanilide hydroxamic acid having a mean particle size of 25 to 45 μm and 70% of a second batch of crystalline suberoylanilide hydroxamic acid having a mean particle size of 130-180 μm.
36. The method of claim 10 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid with unit cell parameters of a=10.9 Å, b=7.9 Å, c=16.4 Å, α=90°, β=97.8°, γ=90°, space group P2 1 /n.
37. The method of claim 11 , wherein the active ingredient is crystalline suberoylanilide hydroxamic acid with unit cell parameters of a=10.9 Å, b=7.9 Å, c=16.4 Å, α=90°, β=97.8°, γ=90°, space group P2 1 /n.
38. The method of claim 1 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
39. The method of claim 2 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
40. The method of claim 10 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
41. The method of claim 11 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
42. The method of claim 24 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
43. The method of claim 25 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
44. The method of claim 36 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
45. The method of claim 37 , wherein the total % volume of active ingredient with particle size less than about 105 microns is about 45-85% and the total % volume of active ingredient with particle size more than about 105 microns is about 55-15%.
46. The method of claim 1 , wherein the cancer is non-Hodgkins Lymphoma.
47. The method of claim 2 , wherein the cancer is non-Hodgkins Lymphoma.
48. The method of claim 10 , wherein the cancer is non-Hodgkins Lymphoma.
49. The method of claim 11 , wherein the cancer is non-Hodgkins Lymphoma.
50. The method of claim 24 , wherein the cancer is non-Hodgkins Lymphoma.
51. The method of claim 25 , wherein the cancer is non-Hodgkins Lymphoma.
52. The method of claim 36 , wherein the cancer is non-Hodgkins Lymphoma.
53. The method of claim 37 , wherein the cancer is non-Hodgkins Lymphoma.
54. The method of claim 38 , wherein the cancer is non-Hodgkins Lymphoma.
55. The method of claim 39 , wherein the cancer is non-Hodgkins Lymphoma.
56. The method of claim 40 , wherein the cancer is non-Hodgkins Lymphoma.
57. The method of claim 41 , wherein the cancer is non-Hodgkins Lymphoma.
58. The method of claim 42 , wherein the cancer is non-Hodgkins Lymphoma.
59. The method of claim 43 , wherein the cancer is non-Hodgkins Lymphoma.
60. The method of claim 44 , wherein the cancer is non-Hodgkins Lymphoma.
61. The method of claim 45 , wherein the cancer is non-Hodgkins Lymphoma.